Core Viewpoint - ST Jinfeng's stock closed at 5.76 yuan, down 1.37%, with a rolling PE ratio of 35.81 times and a total market value of 5.068 billion yuan [1] Company Overview - Hunan Jinfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with key products including various injections and capsules, many of which are exclusive or included in national medical insurance [2] Financial Performance - In Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.90 million yuan, a significant year-on-year decline of 960.04%, with a gross profit margin of 66.62% [3] - The company's PE ratio is 35.81 times, while the industry average is 61.84 times, and the industry median is 35.61 times [3]
ST景峰收盘下跌1.37%，滚动市盈率35.81倍，总市值50.68亿元
Sou Hu Cai Jing·2025-07-21 08:40